Aktienanalyse zu Revolution Medicines Inc (RVMD)RVMDRevolution Medicines Inc

Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Revolution Medicines Inc is a good buy right now due to its recent approval of the drug Rasonque, which has a projected sales potential of $15.1 billion by 2034. The current price is $186.99, with an analyst price target of $259.14 suggesting a 38.3% upside. However, the company is facing significant losses, with a projected EPS of -2.35 for the next earnings report, which is a key risk to consider.